Daniel Tanner, BSc, EMBA, DIC’s Post

How can we make clinical trials more diverse and easier for the patients taking part? Decentralized clinical trials have the potential to boost patient diversity, increase patient-centricity and improve trials for all stakeholders.   In a recent article, I share my thoughts and experiences of decentralization and the benefits for patients, sponsors and industry as a whole, including:   –     its impact so far –     why the pharmaceutical industry is holding back –     next steps and why it’s time to think big.   Plus I share how Cerba Research is embracing decentralization as a key part of our mission to transform research and advance health.   You can read the full article here https://lnkd.in/eTPHP3df